Step by Stepa HemeOncBuddy patient portal

Selpercatinib

Illustration: Selpercatinib

Say it: sel-per-KA-tih-nib · Brand names: Retevmo

Selpercatinib is a targeted pill that blocks a growth signal in cancers with a change in the RET gene.

What it is

Some cancers have a change in a gene called RET. This change tells cancer cells to keep growing. Selpercatinib blocks the RET signal very closely, with fewer effects on other parts of the body.

Often used for

How you get it

It is a capsule or pill you take by mouth twice a day. People usually take it for as long as it works. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

At home

Questions to ask

Side effect guides

Sources

Quick answers

What is Selpercatinib?
Selpercatinib is a targeted pill that blocks a growth signal in cancers with a change in the RET gene. Brand names: Retevmo.
What is Selpercatinib used for?
non-small cell lung cancer with a RET gene change; thyroid cancers with a RET gene change, including medullary thyroid cancer; other solid tumors with a RET gene change.
How is Selpercatinib given?
It is a capsule or pill you take by mouth twice a day. People usually take it for as long as it works. Your schedule may be different.
What are the common side effects of Selpercatinib?
Swelling in the legs, feet, hands, or face. Diarrhea or constipation. Dry mouth. High blood pressure. Feeling tired. Belly pain, nausea, or headache. Rash.
When should I call my care team while taking Selpercatinib?
Yellow skin or eyes, dark urine, or pain on the right side of your belly; New or worse cough, shortness of breath, or chest pain; Bad headache, or blood pressure higher than your team told you to expect; A fast, slow, or pounding heartbeat, or feeling like you might faint; Bleeding that will not stop, black or bloody stools, or coughing up blood; Fever, rash, or muscle and joint pain in the first few weeks, which can be an allergic reaction.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.